• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BECTON, DICKINSON & CO. (SPARKS) BD BBL MGIT PANTA ANTIBIOTIC MIXTURE, LYOPHILIZED; SYSTEM, BLOOD CULTURING

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BECTON, DICKINSON & CO. (SPARKS) BD BBL MGIT PANTA ANTIBIOTIC MIXTURE, LYOPHILIZED; SYSTEM, BLOOD CULTURING Back to Search Results
Model Number 245114
Device Problem Incorrect, Inadequate or Imprecise Result or Readings (1535)
Patient Problem No Patient Involvement (2645)
Event Date 01/12/2021
Event Type  malfunction  
Manufacturer Narrative
Medical device expiration date: unknown.There were multiple 510k numbers reported to be involved.The information for the additional 510k is as follows: pma / 510(k)#: k974883.A device evaluation is anticipated, but has not yet begun.Upon completion of the investigation, a supplemental report will be filed.Device manufacture date: unknown.(b)(4).
 
Event Description
It was reported that prior to use with bd bbl¿ mgit¿ panta¿ antibiotic mixture, lyophilized fungal contamination was discovered.The following information was provided by the initial reporter: the tb lab staff went to reconstitute a vial of panta lot 0149921 with the growth supplement lot 0149929 and noted what appears to be a fungal ball of contamination that was in the liquid supplement and was transferred to the panta when reconstituting it.
 
Event Description
It was reported that prior to use with bd bbl¿ mgit¿ panta¿ antibiotic mixture, lyophilized fungal contamination was discovered.The following information was provided by the initial reporter: the tb lab staff went to reconstitute a vial of panta lot 0149921 with the growth supplement lot 0149929 and noted what appears to be a fungal ball of contamination that was in the liquid supplement and was transferred to the panta when reconstituting it.
 
Manufacturer Narrative
After further evaluation of the complaint, it has been determined that the previously submitted mfr report# 1119779-2021-00204 was sent in error.During investigation it was discovered that it wasn't an issue with the panta vial, it was the supplement.This issue was captured on mfr report# 1119779-2021-00205.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
BD BBL MGIT PANTA ANTIBIOTIC MIXTURE, LYOPHILIZED
Type of Device
SYSTEM, BLOOD CULTURING
Manufacturer (Section D)
BECTON, DICKINSON & CO. (SPARKS)
7 loveton circle
sparks MD 21152
MDR Report Key11282173
MDR Text Key230489644
Report Number1119779-2021-00204
Device Sequence Number1
Product Code MDB
UDI-Device Identifier30382902451144
UDI-Public30382902451144
Combination Product (y/n)N
PMA/PMN Number
K954932
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,other,user facility
Type of Report Initial,Followup
Report Date 03/03/2021
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Other
Device Model Number245114
Device Catalogue Number245114
Device Lot NumberUNKNOWN
Was Device Available for Evaluation? No
Initial Date Manufacturer Received 01/12/2021
Initial Date FDA Received02/04/2021
Supplement Dates Manufacturer Received03/03/2021
Supplement Dates FDA Received03/03/2021
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
-
-